샘플 요청 목록

 카트 문의
시장보고서
상품코드
1744779

세계의 말라리아 백신 시장

Malaria Vaccines
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 371 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

말라리아 백신 세계 시장은 2030년까지 72억 달러에 달할 전망

2024년에 24억 달러로 추정되는 말라리아 백신 세계 시장은 2024년부터 2030년까지 CAGR 20.0%로 성장하여 2030년에는 72억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 프레 적혈구 백신은 CAGR 20.9%를 기록하며 분석 기간 종료시에는 41억 달러에 달할 것으로 예측됩니다. 적혈구 백신 분야 성장률은 분석 기간 동안 CAGR 20.7%로 추정됩니다.

미국 시장은 6억 5,530만 달러로 추정, 중국은 CAGR 26.4%로 성장 예측

미국의 말라리아 백신 시장은 2024년에 6억 5,530만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 16억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 26.4%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 14.8%와 18.2%로 예측됩니다. 유럽에서는 독일이 CAGR 약 16.0%로 성장할 것으로 예측됩니다.

세계의 말라리아 백신 시장 - 주요 동향과 촉진요인 정리

말라리아 백신이 세계 공중보건에 있어 중요한 이정표가 되는 이유는 무엇일까?

말라리아 백신은 세계에서 가장 오래 지속되고 치명적인 전염병과의 싸움에서 획기적인 진전을 이루었습니다. 말라리아는 매년 수십만 명의 목숨을 앗아가고 있으며, 대부분 사하라 사막 이남 아프리카에서 어린이들 사이에서 불균형적으로 발생합니다. 효과적인 예방접종은 오랫동안 세계 말라리아 퇴치의 '잃어버린 고리'로 여겨져 왔습니다. 모기 퇴치, 항말라리아제, 신속 진단 툴은 큰 진전을 이루었지만 백신은 장기적인 예방 효과를 가져와 감염을 줄이고 기존 대책을 보완할 수 있는 잠재력을 가지고 있습니다.

RTS, S/AS01(Mosquilix)에 이어 R21/Matrix-M 백신이 도입된 것은 말라리아 대책이 소극적 예방에서 적극적 예방으로 역사적인 전환을 이루었음을 의미합니다. 이 백신은 가장 치사율이 높은 말라리아 원충을 타겟으로 설계되었습니다. 세계보건기구(WHO)와의 협력과 민관 파트너십을 통해 자원이 제한된 환경에서의 사용이 가속화되고 있습니다. 말라리아 퇴치 목표를 달성하기 위해 의료 시스템이 확장 가능하고 비용 효율적인 수단을 찾고 있는 가운데, 백신 기반 솔루션을 지지하는 분위기가 확산되고 있습니다.

조사, 자금조달, 전개 전략은 어떻게 진화하고 있는가?

말라리아 백신의 상황은 공공 및 자선 사업 투자의 급증, 생명공학 기업의 참여 증가, WHO, Gavi, UNICEF와 같은 세계 조직의 지원으로 빠르게 진화하고 있습니다. 차세대 백신에 대한 임상시험이 확대되고 있으며, 더 광범위한 기생충 균주와 더 오래 지속되는 면역을 목표로 하고 있습니다. 나노입자 기반 제제 및 mRNA 접근법 등 백신 전달 플랫폼의 혁신은 효능과 물류의 제약을 극복하기 위해 검토되고 있습니다.

동시에 가나, 케냐, 말라위 등의 국가에서의 협력적 전개는 미래의 전개 모델에 정보를 제공하고 있습니다. 예방접종 보급을 위해서는 정기적인 예방접종 프로그램과의 통합이 필수적이며, 의료시스템은 콜드체인, 교육, 커뮤니티 참여를 위한 인프라를 구축하고 있습니다. 이와 함께 백신 재고 관리, 접종률 모니터링, 부작용 추적을 위해 수요 예측 도구와 디지털 건강 레지스트리가 채택되고 있습니다. 이러한 생태계 차원의 노력은 과학적 진보를 측정 가능한 공중보건 성과로 연결하기 위해 필수적입니다.

가장 큰 혜택을 받는 지역과 인구는?

사하라 이남 아프리카는 여전히 세계 말라리아 발병의 진원지로 연간 환자 수와 사망자 수의 90% 이상을 차지하고 있으며, 5세 미만 어린이와 임산부는 가장 취약한 집단으로 이들을 대상으로 한 백신 접종 프로그램을 통해 발병률과 사망률을 크게 줄일 수 있습니다. 남아시아, 오세아니아, 중남미 일부를 포함한 광범위한 열대 지역도 기후 변화로 인해 모기 서식지가 확대되고 감염 역학이 변화함에 따라 말라리아 백신의 혜택을 받을 수 있습니다.

난민 캠프, 분쟁 지역, 외딴 시골 지역은 전통적인 예방법을 유지하기 어렵기 때문에 특히 백신에 의존하여 말라리아를 예방하고 있습니다. 도시의 팽창과 매개 모기의 행동 변화도 역학 상황을 변화시키고 있으며, 보건 당국은 위험 프로필을 재평가하고 새로운 핫스팟에 백신을 배치해야 하는 상황에 직면해 있습니다. 백신에 대한 접근성을 국가 말라리아 퇴치 전략 및 기부자 지원과 연계하는 것은 형평성과 효과성을 보장하는 데 매우 중요합니다.

말라리아 백신 시장의 성장은 몇 가지 요인에 의해 초래됩니다. .

말라리아 백신 시장 개척은 말라리아 발병 지역의 질병 부담 증가, 국제 보건기구의 자금 지원 확대, 백신 개발 파이프라인의 가속화 등 여러 요인에 의해 촉진되고 있습니다. 현재 백신의 안전성과 부분적 효과가 입증됨에 따라 백신의 조기 도입과 국가 예방접종 일정에의 편입이 진행되고 있습니다. 정부 조달, 기부자 보조금, 민관 협력은 아프리카 전역과 전 세계 곳곳에 백신을 신속하게 배포할 수 있도록 돕고 있습니다.

항원 설계, 보조제 기술 및 전달 시스템의 발전으로 백신 포트폴리오가 확장되고 면역 내구성이 향상되고 있습니다. 기후와 관련된 말라리아 전파의 변화로 인해 보다 광범위한 지역으로의 확산이 필요하며, 도시화와 인구 이동의 증가로 인해 확장 가능한 예방적 개입의 필요성이 더욱 커지고 있습니다. 말라리아 백신 접종 캠페인의 성공은 더 많은 혁신과 투자를 촉진하고 장기적인 퇴치 활동을 위한 탄탄한 토대를 마련할 수 있을 것으로 기대됩니다.

부문

유형(전 적혈구형, 적혈구형, 멀티 항원형, 기타 유형), 약물 유형(말라리아 원충, 비박스 원충, 아노페레스종), 최종사용자(병원, 전문 클리닉, 재택의료, 기타 최종사용자)

조사 대상 기업 사례(총 32개사)

  • AdvaCare Pharma
  • Ajanta Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Bharat Biotech
  • Bliss GVS Pharma Ltd.
  • CellFree Sciences Co., Ltd.
  • GenVec Inc.
  • GeoVax Labs Inc.
  • GlaxoSmithKline plc(GSK)
  • Hikma Pharmaceuticals PLC
  • Inovio Pharmaceuticals
  • Ipca Laboratories Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanaria Inc.
  • Serum Institute of India Pvt. Ltd.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSM 25.06.20

Global Malaria Vaccines Market to Reach US$7.2 Billion by 2030

The global market for Malaria Vaccines estimated at US$2.4 Billion in the year 2024, is expected to reach US$7.2 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Pre-Erythrocytic Vaccines, one of the segments analyzed in the report, is expected to record a 20.9% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the Erythrocytic Vaccines segment is estimated at 20.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$655.3 Million While China is Forecast to Grow at 26.4% CAGR

The Malaria Vaccines market in the U.S. is estimated at US$655.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 26.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 14.8% and 18.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 16.0% CAGR.

Global Malaria Vaccines Market - Key Trends & Drivers Summarized

Why Are Malaria Vaccines a Pivotal Milestone in Global Public Health?

Malaria vaccines represent a breakthrough in the fight against one of the world’s most persistent and deadly infectious diseases. With malaria claiming hundreds of thousands of lives annually-mostly in Sub-Saharan Africa and disproportionately among children-effective immunization has long been considered the “missing link” in global malaria control strategies. While mosquito control, antimalarial drugs, and rapid diagnostic tools have made significant progress, vaccines offer the potential to provide long-term protection, reduce transmission, and complement existing interventions.

The introduction of the RTS,S/AS01 (Mosquirix) vaccine, followed by the R21/Matrix-M vaccine, marks a historic shift from reactive malaria control to proactive prevention. These vaccines are designed to target the Plasmodium falciparum parasite, the most deadly malaria strain. Their deployment in high-burden countries has already begun, with global health alliances and public-private partnerships accelerating access in resource-limited settings. The momentum behind vaccine-based solutions is building as health systems seek scalable, cost-effective tools to achieve elimination targets.

How Are Research, Funding, and Deployment Strategies Evolving?

The malaria vaccine landscape is evolving rapidly, driven by a surge in public and philanthropic investment, increased engagement from biotech firms, and support from global organizations such as WHO, Gavi, and UNICEF. Clinical trials for next-generation vaccines are expanding, targeting broader parasite strains and longer-lasting immunity. Innovations in vaccine delivery platforms-such as nanoparticle-based formulations and mRNA approaches-are being explored to overcome efficacy and logistics limitations.

Simultaneously, coordinated rollouts in countries like Ghana, Kenya, and Malawi are informing future distribution models. Integration with routine immunization programs is critical to achieving widespread coverage, and health systems are building infrastructure for cold chain, training, and community engagement. In parallel, demand forecasting tools and digital health registries are being employed to manage vaccine inventories, monitor coverage, and track side effects. These ecosystem-level efforts are critical to turning scientific advances into measurable public health outcomes.

Which Regions and Populations Stand to Benefit the Most?

Sub-Saharan Africa remains the epicenter of global malaria incidence, accounting for over 90% of cases and deaths annually. Children under five and pregnant women are the most vulnerable groups, and vaccination programs targeting these populations can significantly reduce morbidity and mortality. The broader tropical belt, including parts of South Asia, Oceania, and Central America, also stands to benefit from malaria vaccines as climate change expands mosquito habitats and alters transmission dynamics.

Refugee camps, conflict zones, and remote rural communities-where traditional prevention methods are difficult to sustain-are particularly reliant on vaccines for malaria control. Urban expansion and changes in vector behavior are also shifting the epidemiological landscape, prompting health authorities to reassess risk profiles and deploy vaccines in emerging hotspots. The alignment of vaccine access with national malaria control strategies and donor support is crucial to ensuring equity and impact.

The Growth in the Malaria Vaccines Market Is Driven by Several Factors…

The growth in the malaria vaccines market is driven by several factors including increasing disease burden in endemic regions, expanded funding from international health organizations, and accelerated vaccine development pipelines. The demonstrated safety and partial efficacy of current vaccines are supporting early adoption and inclusion in national immunization schedules. Government procurement, donor subsidies, and public-private collaboration are facilitating rapid deployment across Africa and beyond.

Advancements in antigen design, adjuvant technology, and delivery systems are expanding the vaccine portfolio and improving immune durability. Climate-related shifts in malaria transmission are pushing the need for broader geographic deployment, while growing urbanization and human mobility are increasing the urgency for scalable and preventive interventions. The success of malaria vaccination campaigns is expected to drive further innovation and investment, establishing a strong foundation for long-term eradication efforts.

SCOPE OF STUDY:

The report analyzes the Malaria Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Pre-Erythrocytic, Erythrocytic, Multi-Antigen, Other Types); Agent Type (Plasmodium Falciparum, Plasmodium Vivax, Anopheles Species); End-Use (Hospitals, Specialty Clinics, Homecare, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AdvaCare Pharma
  • Ajanta Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Bharat Biotech
  • Bliss GVS Pharma Ltd.
  • CellFree Sciences Co., Ltd.
  • GenVec Inc.
  • GeoVax Labs Inc.
  • GlaxoSmithKline plc (GSK)
  • Hikma Pharmaceuticals PLC
  • Inovio Pharmaceuticals
  • Ipca Laboratories Ltd.
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Novavax, Inc.
  • Pfizer Inc.
  • Sanaria Inc.
  • Serum Institute of India Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Malaria Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Burden of Malaria in Sub-Saharan Africa Drives Urgency for Effective Vaccine Development and Deployment
    • WHO Prequalification of RTS,S/AS01 and Other Leading Candidates Strengthens Confidence in Malaria Vaccine Programs
    • Rising Funding From Gavi, CEPI, and Global Health Alliances Supports Procurement and Rollout of Malaria Vaccines
    • Expansion of Pediatric Immunization Campaigns in High-Risk Areas Facilitates Integration of Malaria Vaccines Into National Schedules
    • Breakthroughs in mRNA and Recombinant Protein Platforms Accelerate Innovation in Next-Gen Malaria Vaccine Candidates
    • Rising Use of Vaccine Efficacy Modeling and Genomic Surveillance Supports Targeted Immunization Strategies
    • Push for Seasonal Malaria Vaccine Campaigns in Endemic Zones Enhances Use in Combination With Chemoprevention
    • Increased Global Health Security Emphasis Drives Vaccine Equity and Manufacturing Scale-Up for Malaria Prevention
    • Emergence of Multi-Strain and Multi-Stage Vaccine Candidates Strengthens Long-Term Protection Potential
    • Integration of Malaria Vaccines With Maternal and Infant Health Programs Expands Reach in Rural and Underserved Regions
    • Use of Cold Chain Logistics and Vial-Level Traceability Enhances Efficiency of Malaria Vaccine Distribution
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Malaria Vaccines Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Malaria Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pre-Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pre-Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Pre-Erythrocytic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Erythrocytic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Erythrocytic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Multi-Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Multi-Antigen by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Multi-Antigen by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Homecare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Homecare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Homecare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Plasmodium Falciparum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Plasmodium Falciparum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Plasmodium Falciparum by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Plasmodium Vivax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Plasmodium Vivax by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Plasmodium Vivax by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Anopheles Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Anopheles Species by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Anopheles Species by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • JAPAN
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • CHINA
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • EUROPE
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Malaria Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • FRANCE
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • GERMANY
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Malaria Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • INDIA
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Malaria Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Malaria Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Malaria Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030
  • AFRICA
    • Malaria Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Malaria Vaccines by Type - Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Malaria Vaccines by Type - Percentage Breakdown of Value Sales for Pre-Erythrocytic, Erythrocytic, Multi-Antigen and Other Types for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Malaria Vaccines by End-Use - Homecare, Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Malaria Vaccines by End-Use - Percentage Breakdown of Value Sales for Homecare, Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Malaria Vaccines by Agent Type - Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Malaria Vaccines by Agent Type - Percentage Breakdown of Value Sales for Plasmodium Falciparum, Plasmodium Vivax and Anopheles Species for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제